June 29, 2012
Save
This article is more than 5 years old. Information may no longer be current.
Addition of abiraterone to HT could eliminate tumors in some men with high-risk prostate cancer
The study presented by Mary-Ellen Taplin, MD, and colleagues found that the addition of abiraterone during 6 months of hormonal therapy prior to surgery eliminated or nearly eliminated tumors in one-third of men with localized high-risk prostate cancer. Here, Donald L. Trump, MD, reviews the implications of these results.